<DOC>
	<DOC>NCT00506805</DOC>
	<brief_summary>Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.</brief_summary>
	<brief_title>Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies</brief_title>
	<detailed_description />
	<criteria>&gt;18 years old histologically confirmed solid tumor malignancy refractory to available therapy or for which no therapy is available adequate organ function CNS malignancy significant GI disease at risk for prolonged QT interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>solid tumor malignancy; Hsp90</keyword>
</DOC>